Allulose Tablet Composition for Direct Compression Hardness

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing technologies are unable to produce tablets with significant amounts of allulose due to its lack of compressibility and flow properties, making it difficult to achieve satisfactory hardness and ejection forces using direct compression methods.

Innovation Solution

Allulose is purified to a purity of 90.0% and adjusted to a mean volume diameter of 45-250 µm, allowing it to act as a direct compression excipient in the presence of magnesium stearate, forming tablets with a hardness greater than 50 N and ejection force less than 1200 N.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If direct compression method is used to produce tablets with allulose, then manufacturing simplicity and cost are improved, but tablet hardness and compressibility deteriorate due to allulose's poor flow and compressibility properties

Engineering Contradiction:
Improvemanufacturing simplicityVSAvoidtablet hardness
Core Design Contradiction:
Ease of manufactureVSStrength

Solution Approach 1:

The patent changes the physical parameters of allulose by controlling particle size (D10: 10-50 µm, D50: 50-150 µm, D90: 150-300 µm) and purity (≥90%), which transforms allulose from an incompressible material into one suitable for direct compression while achieving adequate tablet hardness

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite powder system combining allulose with magnesium stearate (0.5-5% by weight), where the lubricant component compensates for allulose's poor compressibility and flow properties, enabling direct compression while maintaining tablet integrity

Inventive Principle:
Principle #40Composite materials

2Reliability

If allulose content in tablets is increased to provide health benefits, then therapeutic effectiveness is improved, but ejection force and manufacturing difficulty worsen due to allulose's inherent properties

Engineering Contradiction:
Improvetherapeutic effectivenessVSAvoidejection force
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

Magnesium stearate acts as an intermediary lubricant between allulose particles and the metal die surface, reducing friction and ejection force by 50-90%, thereby enabling high allulose content (≥30% by weight) tablets to be manufactured without excessive ejection forces

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent optimizes the particle size distribution parameters of allulose (D10: 10-50 µm, D50: 50-150 µm, D90: 150-300 µm) to improve flow properties and reduce interparticle friction, which directly lowers ejection force while maintaining high allulose content

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The solution enables the production of tablets with allulose content exceeding 30% by weight, maintaining hardness and reducing ejection forces, thus overcoming the limitations of direct compression techniques.

Implementation Method 1

the mass must remain in the compact form once the compression force is removed. Hence, the directly compressible composition should allow the obtaining of tablets of sufficient hardness

Methodology Applied
Scientific EffectCompression: Compression

Implementation Method 2

lubricants, whose role is to enable the ejection of matrices, newly formed tablets

Methodology Applied
Scientific EffectLubrication: Lubrication

Data Source

PatentEP3171710B1Sugar compositions for tableting by direct compression
Publication Date: 2025.12.03 ROQUETTE FRERES SA
  • EP3171710B1 patent drawingFigure 1~2
  • EP3171710B1 patent drawingFigure 3

AI summary

The present invention relates to directly compressible compositions comprising more than 30 % by weight of allulose, and to tablets obtainable thereof.